GH1 and breast carcinoma: Notably, intratumoral GH abundance in hepatocellular, uterine, and breast cancer correlates highly with disease progression, and is an adverse mortality determinant (Kong et al., 2016; Perry et al., 2017; Wu et al., 2011).